These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 28322895

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Baicalin down-regulating hepatitis B virus transcription depends on the liver-specific HNF4α-HNF1α axis.
    Xia C, Tang W, Geng P, Zhu H, Zhou W, Huang H, Zhou P, Shi X.
    Toxicol Appl Pharmacol; 2020 Sep 15; 403():115131. PubMed ID: 32687838
    [Abstract] [Full Text] [Related]

  • 3. Protocatechuic acid inhibits hepatitis B virus replication by activating ERK1/2 pathway and down-regulating HNF4α and HNF1α in vitro.
    Dai XQ, Cai WT, Wu X, Chen Y, Han FM.
    Life Sci; 2017 Jul 01; 180():68-74. PubMed ID: 28504115
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S, Herbers U, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2011 Nov 01; 18(11):804-14. PubMed ID: 20887378
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.
    Gastroenterology; 2012 Sep 01; 143(3):619-628.e1. PubMed ID: 22643350
    [Abstract] [Full Text] [Related]

  • 7. Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis.
    Pan Y, Ke Z, Ye H, Sun L, Ding X, Shen Y, Zhang R, Yuan J.
    Inflamm Res; 2019 Dec 01; 68(12):1025-1034. PubMed ID: 31531682
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr 01; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 9. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct 01; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 10. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
    Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L, Zhang X.
    Cancer Lett; 2017 Apr 28; 392():94-104. PubMed ID: 28192212
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.
    Arab J Gastroenterol; 2014 Mar 28; 15(1):1-5. PubMed ID: 24630505
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH, Ren XN, Chen LX, Shi BS, Xu CH, Fang Z, Liu X, Chen JL, Zhang XN, Hu YW, Zhou XH.
    World J Gastroenterol; 2015 Mar 28; 21(12):3527-36. PubMed ID: 25834317
    [Abstract] [Full Text] [Related]

  • 16. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.
    J Viral Hepat; 2012 Oct 28; 19(10):724-31. PubMed ID: 22967104
    [Abstract] [Full Text] [Related]

  • 17. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF, Lai CL.
    J Gastroenterol Hepatol; 2011 Jan 28; 26 Suppl 1():138-43. PubMed ID: 21199525
    [Abstract] [Full Text] [Related]

  • 18. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 19. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Nov 21; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.
    J Gastroenterol; 2017 May 21; 52(5):641-651. PubMed ID: 27699721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.